Lineage Cell Therapeutics (LCTX) Other Operating Expenses (2018 - 2025)
Historic Other Operating Expenses for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Q3 2025 value amounting to $5000.0.
- Lineage Cell Therapeutics' Other Operating Expenses fell 8684.21% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15.1 million, marking a year-over-year increase of 827444.44%. This contributed to the annual value of $334000.0 for FY2024, which is 5022.35% down from last year.
- As of Q3 2025, Lineage Cell Therapeutics' Other Operating Expenses stood at $5000.0, which was down 8684.21% from $14.9 million recorded in Q2 2025.
- Lineage Cell Therapeutics' Other Operating Expenses' 5-year high stood at $14.9 million during Q2 2025, with a 5-year trough of $5000.0 in Q3 2025.
- Its 3-year average for Other Operating Expenses is $1.6 million, with a median of $108500.0 in 2023.
- Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Other Operating Expenses was 3371590.91% (2025), while the steepest drop was 8684.21% (2025).
- Over the past 3 years, Lineage Cell Therapeutics' Other Operating Expenses (Quarter) stood at $169000.0 in 2023, then fell by 8.88% to $154000.0 in 2024, then crashed by 96.75% to $5000.0 in 2025.
- Its last three reported values are $5000.0 in Q3 2025, $14.9 million for Q2 2025, and $36000.0 during Q1 2025.